{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:30:39Z","timestamp":1753893039549,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"Background<\/jats:title>This study aims to analyze and compare the impact of the diagnosis-intervention packet (DIP) payment on inpatient medical costs for hematologic malignancies (HM) and solid tumors (ST) patients, and to explore its implications for hospital financial sustainability and payment reform.<\/jats:p><\/jats:sec>Methods<\/jats:title>Using a retrospective research design, this study focused on HM and ST patients treated before and after the implementation of the DIP payment at a large tertiary general hospital in A city, located in the eastern coastal area of China. Data were collected, organized, and analyzed to compare differences in inpatient medical costs between HM and ST patients and to examine their impact on the income of the department of hematology.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 5,115 cases from both before and after the DIP payment implementation. Post-implementation, the median inpatient medical costs per case decreased from 5,544.45 CNY to 5,169.66 CNY, with costs for both HM and ST hospitalizations showing a decline. Specifically, the inpatient medical costs per case for HM were 5,722.46 (4,471.08, 11,508.78) CNY, higher than those for ST at 4,779.28 (3,056.70, 7,152.64) CNY, and exceeding the DIP payment standard. Wilcoxon signed-rank test and regression analysis indicated that HM inpatient medical costs surpass the standard payments, resulting in financial losses. All findings were statistically significant (p<\/jats:italic>\u202f&lt;\u202f0.05). These results suggest a structural mismatch between DIP reimbursement rates and the resource intensity of hematologic malignancy treatment, which may jeopardize the financial viability of hematology departments.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Despite a reduction in median inpatient medical costs following the implementation of the DIP payment, departments treating HM patients continue to experience financial losses due to costs exceeding the payment standard. These findings highlight the need to refine DIP payment standards to better account for clinical complexity and technological advancements. Future reforms should aim to improve alignment between payments and actual care needs to ensure financial sustainability and equity. However, this study is limited by its single-center design and lack of control for potential confounders. Broader multi-center studies with more detailed clinical data are needed to validate and extend these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1453367","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:14:22Z","timestamp":1746594862000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The impacts of diagnosis-intervention packet payment on inpatient medical costs for hematologic malignancies and solid tumors: evidence from a retrospective study in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Huiping","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunqing","family":"She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaogui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/hpm.2669","article-title":"A scoping review of empirical evidence on the impacts of the DRG introduction in Germany and Switzerland","volume":"34","author":"Kone","year":"2019","journal-title":"Int J Health Plan Manag"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/20479700.2020.1782663","article-title":"Investigation of the impact of DRG based reimbursement mechanisms on quality of care, capacity utilization, and efficiency-a systematic review","volume":"14","author":"Barouni","year":"2021","journal-title":"Int J Healthc Manag"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/1833358318795804","article-title":"A review of the complexity adjustment in the Korean diagnosis-related group (KDRG)","volume":"49","author":"Kim","year":"2020","journal-title":"Health Inf Manag J"},{"year":"2020","key":"ref4"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.21037\/hbsn-2020-8","article-title":"Diagnosis-related groups (DRG) pricing and payment policy in China: where are we?","volume":"9","author":"Yu","year":"2020","journal-title":"Hepatobil Surg Nutr"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5582\/bst.2017.01289","article-title":"Diagnosis-related group (DRG)-based case-mix funding system, a promising alternative for fee for service payment in China","volume":"12","author":"Zhao","year":"2018","journal-title":"Biosci Trends"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1069131","DOI":"10.3389\/fpubh.2023.1069131","article-title":"The impacts of diagnosis-intervention packet payment on the providers\u2019 behavior of inpatient care\u2014evidence from a national pilot city in China","volume":"11","author":"Ding","year":"2023","journal-title":"Front Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.22541\/au.167819115.59006907\/v1","article-title":"Evaluate the effectiveness of diagnosis-intervention packet (DIP) reform among inpatients diagnosed with cancer in Guangzhou, China: interrupted time-series analyses based on a 5-year research period","author":"Chen","year":"2023","journal-title":"Authorea Preprints"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/hpm.3739","article-title":"Impacts of a new diagnosis-related group point payment system on children's medical services in China: length of stay and costs","volume":"39","author":"Wang","year":"2024","journal-title":"Int J Health Plann Manag"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/cancers14071605","article-title":"Divergent patterns in care utilization and financial distress between patients with blood cancers and solid tumors: a National Health Interview Survey Study, 2014\u20132020","volume":"14","author":"Su","year":"2022","journal-title":"Cancers"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jval.2018.07.154","article-title":"Healthcare utilization and cost at the end of life of hematological malignancies and solid tumors in South Korea","volume":"21","author":"Yang","year":"2018","journal-title":"Value Health"},{"year":"2017","author":"Xi","key":"ref12"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1186\/s12913-021-07119-3","article-title":"Spatial analysis and evaluation of medical resource allocation in China based on geographic big data","volume":"21","author":"Wan","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/healthcare11060829","article-title":"Evaluation of the medical resource allocation: evidence from China","volume":"11","author":"Xi","year":"2023","journal-title":"Healthcare"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.vhri.2021.12.003","article-title":"Policy updates on access to and affordability of innovative medicines in China","volume":"30","author":"Liu","year":"2022","journal-title":"Value Health Reg Issues"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"923209","DOI":"10.3389\/fphar.2022.923209","article-title":"The change of drug utilization in China\u2019s public healthcare institutions under the \u201c4+ 7\u201d centralized drug procurement policy: evidence from a natural experiment in China","volume":"13","author":"Lu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref17","first-page":"106","article-title":"Visualized analyses of the research on DRG and DIP in China","author":"Zhou","year":"2023"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/RMHP.S502474","article-title":"Impact of China\u2019s diagnosis-intervention packet policy on hospitalization costs for patients with malignant tumors: a 2019\u20132022 interrupted time series analysis","volume":"18","author":"Zhang","year":"2025","journal-title":"Risk Manag Healthc Policy"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2147\/RMHP.S463276","article-title":"Effects of a diagnosis-related group payment reform on length and costs of hospitalization in Sichuan, China: a synthetic control study","volume":"17","author":"Liu","year":"2024","journal-title":"Risk Manag Healthc Policy"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2147\/RMHP.S498634","article-title":"Cost shifting in lung Cancer inpatient care under diagnosis-intervention packet reform: a pilot study in China","volume":"18","author":"Tan","year":"2025","journal-title":"Risk Manag Healthc Policy"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/heapol\/czae022","article-title":"Hospital response to a new case-based payment system in China: the patient selection effect","volume":"39","author":"Zhang","year":"2024","journal-title":"Health Policy Plan"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.3390\/cancers13225606","article-title":"A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma","volume":"13","author":"Seefat","year":"2021","journal-title":"Cancers"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/bmj.f3197","article-title":"Diagnosis related groups in Europe: moving towards transparency, efficiency, and quality in hospitals?","volume":"346","author":"Busse","year":"2013","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s15010-025-02507-x","article-title":"Caseload, clinical spectrum and economic burden of infectious diseases in patients discharged from hospitals in Germany","author":"Stocker","year":"2025","journal-title":"Infection"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41409-024-02228-z","article-title":"Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective","volume":"59","author":"Ahmadi","year":"2024","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1453367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:14:23Z","timestamp":1746594863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1453367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":30,"alternative-id":["10.3389\/fpubh.2025.1453367"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1453367","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"article-number":"1453367"}}